Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1113 • ACR Convergence 2022
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
Thomas Dörner¹, Antónia Szántó², Jui-Cheng Tseng³, Martin Kaul⁴, Ilona Pylvaenaeinen⁵, Malika Hanser⁶, Nasri Abdallah⁶, Bruno Cenni⁶ and Richard Siegel⁶, ¹Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Debreceni Egyetem Klinikai Centrum, Debrecen, Hungary, ³Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁴Independent Consultant, Neustadt, Germany, ⁵Early Development Analytics, Novartis Pharmaceutical AG, Basel, Switzerland, ⁶Novartis Institutes for BioMedical Research, Basel, Switzerland
Background/Purpose: Sjögren's syndrome (SS) is a systemic autoimmune disease of unknown etiology characterized by B-cell hyperactivation, lymphoid infiltration, progressive destruction of exocrine glands, and various…
Abstract Number: 2019 • ACR Convergence 2022
Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells
Mandi Wiley¹, Bhuwan Khatri¹, Kandice Tessneer¹, Michelle Joachims¹, Anna Stolarczyk¹, Anna Nagel¹, Astrid Rasmussen¹, Professor Simon Bowman², Lida Radfar³, Roald Omdal⁴, Marie Wahren-Herlenius⁵, Blake Warner⁶, Torsten Witte⁷, Roland Jonsson⁸, Maureen Rischmueller⁹, Patrick Gaffney¹, Judith James¹, Lars Ronnblom¹⁰, Hal Scofield¹, Xavier Mariette¹¹, Fai Ng¹², Gunnel Nordmark¹⁰, Betty Tsao¹³ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University Hospitals Birmingham, Birmingham, United Kingdom, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Stavanger University, Stavanger, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Institutes of Health, Bethesda, MD, ⁷MH-Hannover, Hannover, Germany, ⁸University of Bergen, Bergen, Norway, ⁹RheumatologySA, Adelaide, Australia, ¹⁰Uppsala University, Uppsala, Sweden, ¹¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹²Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹³Medical University of South Carolina, Charleston, SC
Background/Purpose: Sjögren's Disease (SjD) and Systemic Lupus Erythematosus (SLE) share several characteristics and have similar genome-wide significant associations in the DDX6-CXCR5 locus. Fine mapping of…
Abstract Number: 2035 • ACR Convergence 2022
Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease
Dizon Brian¹, Matthew Basiaga², Sara Stern³, Akaluck Thatayatikom⁴, seunghee cha⁵, Scott Lieberman⁶, Hemalatha Srinivasalu⁷ and on behalf of CARRA and the childhood Sjogren's workgroup⁸, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Mayo Clinic, Inver Grove Heights, MN, ³University of Utah, Salt Lake City, UT, ⁴AdventHealth, Orlando, FL, ⁵University of Florida, Gainesville, FL, ⁶University of Iowa, Iowa City, IA, ⁷Children's National Hospital, Washington, DC, ⁸Childhood Arthritis and Rheumatology Research Alliance, Bethesda, MD
Background/Purpose: Sjögren's disease is a rare condition in children. Diagnosis is often delayed because of the lack of pediatric-specific guidelines for childhood Sjögren's disease (cSjD).…
Abstract Number: 2051 • ACR Convergence 2022
Targeting Janus Kinase Pathway in Sjogren’s Disease Corrects IFN-Driven Inflammation and Epithelial Dysfunction
Sarthak Gupta¹, Eiko Yamada², Hiroyuki Nakamura², Zohreh Khavandgar³, Daniel Martin², Mayank Tandon⁴, Ilias Alevizos⁵, Shyh-Ing Jang², Paola Perez², Kalie Dominick², Thomas Pranzatelli², Alan Baer⁶, john chiorini⁴ and Blake Warner³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²NIDCR, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴NIH, Bethesda, MD, ⁵Horizon Therapeutics, Gaithersburg, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Many of the inflammatory cytokines implicated in Sjogren's Disease (SjD) pathogenesis, in particular Type I and II interferons (IFNs), signal through Janus kinases (JAK)…
Abstract Number: 1120 • ACR Convergence 2022
Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues
Marcin Radziszewski¹, Mandi Wiley¹, Bhuwan Khatri¹, Kandice Tessneer¹, Astrid Rasmussen¹, Professor Simon Bowman², Lida Radfar³, Roald Omdal⁴, Marie Wahren-Herlenius⁵, Blake Warner⁶, Torsten Witte⁷, Roland Jonsson⁸, Maureen Rischmueller⁹, Patrick Gaffney¹, Judith James¹, Lars Ronnblom¹⁰, R. Hal Scofield³, Xavier Mariette¹¹, Marta Alarcon-Riquelme¹², Fai Ng¹³, Gunnel Nordmark¹⁰, Umesh Deshmukh¹, A. Darise Farris¹ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University Hospitals Birmingham, Birmingham, United Kingdom, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Stavanger University, Stavanger, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Institutes of Health, Bethesda, MD, ⁷MH-Hannover, Hannover, Germany, ⁸University of Bergen, Bergen, Norway, ⁹RheumatologySA, Adelaide, Australia, ¹⁰Uppsala University, Uppsala, Sweden, ¹¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease characterized by reduced function of exocrine glands, but also has systemic manifestations affecting multiple organs, including abnormal…
Abstract Number: 2020 • ACR Convergence 2022
Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
Anna Nagel¹, Bhuwan Khatri¹, Marcin Radziszewski¹, Mandi Wiley¹, Anna Stolarczyk¹, Michelle Joachims¹, Kandice Tessneer¹, Astrid Rasmussen¹, Professor Simon Bowman², Lida Radfar³, Roald Omdal⁴, Marie Wahren-Herlenius⁵, Blake Warner⁶, Torsten Witte⁷, Roland Jonsson⁸, Maureen Rischmueller⁹, Patrick Gaffney¹, Judith James¹, Lars Ronnblom¹⁰, Hal Scofield¹, Xavier Mariette¹¹, Marta Alarcon-Riquelme¹², Fai Ng¹³, Gunnel Nordmark¹⁰, Qing Sun¹⁴, Kwangwoo Kim¹⁵, Sang-Cheol Bae¹⁶, Betty Tsao¹⁴, A. Darise Farris¹ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University Hospitals Birmingham, Birmingham, United Kingdom, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Stavanger University, Stavanger, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Institutes of Health, Bethesda, MD, ⁷MH-Hannover, Hannover, Germany, ⁸University of Bergen, Bergen, Norway, ⁹RheumatologySA, Adelaide, Australia, ¹⁰Uppsala University, Uppsala, Sweden, ¹¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Kyung Hee University, Seoul, Republic of Korea, ¹⁶Hanyang University Medical Center, Seoul, Republic of Korea
Background/Purpose: Dysregulated autophagy is implicated in systemic lupus erythematous (SLE) and Sjögren's disease (SjD), including dysregulated expression of Autophagy-related gene 5 (ATG5) and Autophagy Related…
Abstract Number: 2036 • ACR Convergence 2022
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
Andres Martinez¹, Julieta Morbiducci¹, Constanza Arguissain¹, Maria Tamborenea¹, Marisel Bejarano², Lucia Castorino¹ and Anastasia Secco¹, ¹Rivadavia Hospital, Buenos Aires, Argentina, ²Rivadavia´s Hospital, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
Abstract Number: 2070 • ACR Convergence 2022
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
Sarah Dyball¹, John Reynolds², Hector Chinoy³, Ariane Herrick¹, Sahena Haque⁴, Ellen Bruce⁵, Sophia Naz⁶, Ben Parker⁷ and Ian N. Bruce⁸, ¹The University of Manchester, Manchester, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³The University of Manchester, Sale, United Kingdom, ⁴Manchester Foundation Trust, Manchester, United Kingdom, ⁵Kellgren Centre for Rheumatology, Manchester, United Kingdom, ⁶Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ⁷Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁸Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…
Abstract Number: 0298 • ACR Convergence 2021
The Clinical Phenotype of Isolated Ocular and Oral Dryness in Sjogren Syndrome, Fulfilling the 2016 ACR-EULAR Classification Criteria
Loukas Chatzis¹, Andreas Goules², Chiara Baldini³, Vasilis Pezoulas⁴, Ourania Argyropoulou¹, Paraskevi Voulgari⁵, Sofia Kouvelioti⁶, Dimitrios Fotiadis⁷, Fotini Skopouli⁸, Haralampos Moutsopoulos⁹ and Athanasios Tzioufas¹, ¹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, ³University of Pisa, Pisa, Italy, ⁴Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece, Ioannina, Greece, ⁵Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁶Leophoros Kifisias 81, Ampelokipoi, Athens, Greece, ⁷Department of Biomedical Research, Institute of Molecular Biology and Biotechnology, FORTH, Ioannina, Greece, Ioannina, Greece, ⁸Department of Nutrition and Clinical Dietetics, Harokopio University of Athens, Athens, Greece, ⁹Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: Dry mouth and eyes are the main clinical features of Sjögren’s syndrome (SS), although a minority of patients present without sicca manifestations and isolated…
Abstract Number: 0314 • ACR Convergence 2021
PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome
Dana DiRenzo¹, Susan Robinson², Clifton Bingham¹, Alan Baer³ and Thomas Grader-Beck¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjogren’s Syndrome (SS) is a systemic autoimmune disease that has considerable impact on health-related quality of life (HRQL). The European League Against Rheumatism (EULAR)…
Abstract Number: 0987 • ACR Convergence 2021
Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial
Elena Pontarini¹, Farzana Chowdhury¹, Elisabetta Sciacca¹, Sofia Grigoriadou¹, Felice Rivellese¹, Davide Lucchesi¹, Katriona Goldmann¹, Liliane Fossati-Jimack¹, Paul Emery², Wan-Fai NG³, Nurhan Sutcliffe⁴, Colin C Everett⁵, Catherine Fernandez⁵, Anwar Tappuni⁶, Myles Lewis¹, Costantino Pitzalis⁷, Simon J Bowman⁸ and Michele Bombardieri¹, ¹Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ³Translational and Clinical Research Institute, Newcastle University,, Newcastle, United Kingdom, ⁴Royal London Hospital, Bart’s Health NHS Trust, London, United Kingdom, ⁵Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁶Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Queen Mary University of London, London, United Kingdom, ⁷Queen Mary University of London, London, United Kingdom, ⁸Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: The pathogenic role of B-cells in primary Sjögren’s Syndrome (pSS) is well established and B cell abnormalities are hallmarks of the disease. Because of…
Abstract Number: 0299 • ACR Convergence 2021
Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios
Sara McCoy¹, Christie Bartels², Scott Hetzel¹ and Jeffrey VanWormer³, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Marshfield Research Institute, Marshfield, WI
Background/Purpose: Sjӧgren’s syndrome (SS) is the most female predominant systemic autoimmune disease, with peak onset around perimenopause. Estrogen appears to protect against SS, but prior…
Abstract Number: 0315 • ACR Convergence 2021
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Samantha Wratten¹, Natasha Griffiths², Carl Cooper², Jessica Flynn², Rebecca Hall³, Linda Abetz-Webb², Wolfgang Hueber⁴, Briana Ndife⁵ and Pushpendra Goswami⁴, ¹Adelphi Values, Macclesfield, United Kingdom, ²Adelphi Values, Bollington, United Kingdom, ³Adelphi Values Ltd, Bollington, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis, East Hanover, NJ
Background/Purpose: The aim of this study was to gain qualitative patient feedback on the appropriateness of two Patient Reported Outcome (PRO) measures as assessments of…
Abstract Number: 1440 • ACR Convergence 2021
Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
Sara McCoy, Ilya Gurevic, Maxwell Parker and Jacques Galipeau, University of Wisconsin, Madison, WI
Background/Purpose: Sjӧgren’s syndrome (SS) is a systemic autoimmune disease that is associated with a lymphoma risk 14-fold that of the general population. Greater focal lymphocytic…
Abstract Number: 0300 • ACR Convergence 2021
Salivary Gland Epithelial Cells Transcriptomic Analysis Highlight Their Potential Involvement in Extracellular Matrix Modification in Sjögren’s Syndrome
Elodie Rivière¹, Juliette Pascaud¹, Franck Letourneur², Gaetane Nocturne¹ and Xavier Mariette³, ¹Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184 ; Rheumatology, APHP, Université Paris Saclay, Le Kremlin Bicêtre, France, ²Plateforme Génomique : GENOM'IC — Institut Cochin, Paris, France, ³Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Salivary gland epithelial cells (SGECs) participate to the hyper activation of the immune system in primary Sjögren’s syndrome (pSS). This study aimed to analyze…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].